These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 1434844)

  • 1. Has IL2 a role in the management of minimal residual disease for acute leukemia?
    Foa R; Meloni G; Guarini A; Mandelli F; Gavosto F
    Leukemia; 1992 Nov; 6 Suppl 4():92-4. PubMed ID: 1434844
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interleukin 2 (IL2) in the management of acute myeloid leukemia: clinical and biological findings.
    Foa R; Meloni G; Guarini A; Vignetti M; Marchis D; Tosti S; Tos AG; Vischia F; Mandelli F; Gavosto F
    Leukemia; 1992; 6 Suppl 3():115S-116S. PubMed ID: 1602806
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interleukin-2 and gene therapy in the management of acute lymphoblastic leukaemia.
    Foa R
    Baillieres Clin Haematol; 1994 Jun; 7(2):421-34. PubMed ID: 7803910
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of residual disease in acute leukemia patients with recombinant interleukin 2 (IL2): clinical and biological findings.
    Foa R; Meloni G; Tosti S; Novarino A; Fenu S; Guarini A; Cardona S; Gillio Tos A; Gavosto F; Mandelli F
    Bone Marrow Transplant; 1990 Jul; 6 Suppl 1():98-102. PubMed ID: 2202476
    [No Abstract]   [Full Text] [Related]  

  • 5. Treatment of minimal residual disease in acute leukemia--focus on immunotherapeutic options.
    Simonsson B; Nilsson BI; Rowe JM
    Leukemia; 1992 Nov; 6 Suppl 4():124-34. PubMed ID: 1279326
    [No Abstract]   [Full Text] [Related]  

  • 6. IL2 treatment for cancer: from biology to gene therapy.
    Foa R; Guarini A; Gansbacher B
    Br J Cancer; 1992 Dec; 66(6):992-8. PubMed ID: 1457368
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interleukin-2-based immunotherapy in the management of minimal residual disease in acute leukemia patients.
    Foa R; Meloni G; Guarini A; Vignetti M; Marchis D; Tosti S; Gillio Tos A; Mandelli F; Gavosto F
    Recent Results Cancer Res; 1993; 131():207-14. PubMed ID: 8210640
    [No Abstract]   [Full Text] [Related]  

  • 8. Peripheral blood and bone marrow immunophenotypic and functional modifications induced in acute leukemia patients treated with interleukin 2: evidence of in vivo lymphokine activated killer cell generation.
    Foa R; Guarini A; Gillio Tos A; Cardona S; Fierro MT; Meloni G; Tosti S; Mandelli F; Gavosto F
    Cancer Res; 1991 Feb; 51(3):964-8. PubMed ID: 1988139
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Interleukin-2 and its use in hemo-proliferative disorders].
    Hellmann A
    Acta Haematol Pol; 1994; 25(2 Suppl 1):142-7. PubMed ID: 8067199
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lymphokine activated killer (LAK) activity in lymphoproliferative disorders.
    Foa R; Fierro MT; Raspadori D; Bonferroni M; Cardona S; Liao XS; Cesano A; Matera L; Gillio Tos A; Tola E
    Bone Marrow Transplant; 1989 Jan; 4 Suppl 1():153-5. PubMed ID: 2653494
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The role of interleukin-2--based immunotherapy in hematological malignancies].
    Ackerstein A; Toren A; Slavin S; Nagler A
    Harefuah; 1996 May; 130(9):613-7. PubMed ID: 8794642
    [No Abstract]   [Full Text] [Related]  

  • 12. Does interleukin-2 have a role in the management of acute leukemia?
    Foa R
    J Clin Oncol; 1993 Sep; 11(9):1817-25. PubMed ID: 8355048
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IL-2 activated cell-mediated immunotherapy: control of minimal residual disease in malignant disorders by allogeneic lymphocytes and IL-2.
    Slavin S; Ackerstein A; Kedar E; Weiss L
    Bone Marrow Transplant; 1990 Jul; 6 Suppl 1():86-90. PubMed ID: 2390644
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospects for interleukin-2 therapy in hematologic malignant neoplasms.
    Malkovska V; Sondel PM
    J Natl Cancer Inst Monogr; 1990; (10):69-72. PubMed ID: 2189478
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interleukin 2 in the management of acute leukaemia.
    Foa R
    Br J Haematol; 1996 Jan; 92(1):1-8. PubMed ID: 8562379
    [No Abstract]   [Full Text] [Related]  

  • 16. Role of postinduction immunotherapy in acute myeloid leukemia.
    Klingemann HG
    Leukemia; 1996 Apr; 10 Suppl 1():S21-2. PubMed ID: 8618464
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of minimal residual disease in acute myelogenous leukemia (AML): focus on immunotherapeutic options.
    Simonsson B
    Leukemia; 1996 Jun; 10 Suppl 2():s44-5. PubMed ID: 8649052
    [No Abstract]   [Full Text] [Related]  

  • 18. Therapeutic potency of IL2-caspase 3 targeted treatment in a murine experimental model of inflammatory bowel disease.
    Shteingart S; Rapoport M; Grodzovski I; Sabag O; Lichtenstein M; Eavri R; Lorberboum-Galski H
    Gut; 2009 Jun; 58(6):790-8. PubMed ID: 18978179
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Minimal residual disease in hematological neoplasms].
    Cajozzo A
    Recenti Prog Med; 1990 Oct; 81(10):655-7. PubMed ID: 2291010
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Problems and prospects of new immunotherapeutic approaches.
    Fridman WH; Mathiot C; Michon J; Teillaud JL; Dorval T; Zucker JM; Pouillart P
    Cancer Detect Prev; 1990; 14(6):657-60. PubMed ID: 2257565
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.